Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistDr. Melanie M. Hoppers at Physicians Quality Care failed to conduct clinical drug investigations in accordance with FDA requirements during an inspection of two studies, including a Phase IIIb trial of baloxavir marboxil for influenza transmission reduction. The primary violation identified was failure to ensure the investigations were conducted according to the investigational plans as required under 21 CFR 312.60, indicating inadequate adherence to protocol requirements and applicable regulations governing clinical research and human subject protection. The FDA inspection, conducted in December 2022 as part of the Bioresearch Monitoring Program, documented these deficiencies through Form FDA 483 observations, which Dr. Hoppers addressed in a January 2023 response that the agency found insufficient.